Janux Therapeutics, Inc. (JANX) vs MannKind Corporation (MNKD)

Janux Therapeutics, Inc. and MannKind Corporation are both Biotechnology companies. Janux Therapeutics, Inc. and MannKind Corporation are of similar size ($1.1B and $1.0B). Janux Therapeutics, Inc. grew revenue faster over the last twelve months: 83.9% against 30.5%. MannKind Corporation has the higher net margin (−11.1% vs −427.5%) and the higher return on invested capital (2.36% vs 0.00%). Across the 16 metrics below, MannKind Corporation leads on 11 and Janux Therapeutics, Inc. on 5.

Valuation

Metric JANX MNKD Biotechnology median
P/E n/m n/m 7.88
P/S 42.74 2.62 11.47
P/B 1.11 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 42.70 0.74
EV/Sales 2.29 3.41 10.73
Earnings yield (10.06%) (3.89%) (28.84%)
Free cash flow yield (4.09%) (1.76%) (23.03%)

Profitability

Metric JANX MNKD Biotechnology median
Gross margin 100.00% 75.39% 65.16%
Operating margin (598.15%) 2.34% 0.00%
Net margin (427.47%) (11.08%) 0.00%
Free cash flow margin (174.69%) (4.61%) 0.00%
Return on equity (10.70%) 71.36% (57.72%)
Return on assets (10.06%) (7.62%) (49.22%)
Return on invested capital 0.00% 2.36% 0.00%

Growth

Metric JANX MNKD Biotechnology median
Revenue growth (TTM) 83.92% 30.46% 5.64%
EPS growth (last fiscal year) (42.97%) (80.00%) —
Revenue growth, 5-year CAGR — 39.89% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric JANX MNKD Biotechnology median
Debt to equity 0.00 (6.28) 0.00
Current ratio 16.35 1.72 4.73
Net debt to EBITDA 5.58 5.32 0.96

Dividend

Metric JANX MNKD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric JANX MNKD Biotechnology median
Market cap 1.02b 1.06b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack